Carl Zeiss Meditec Signs $1 Billion Deal to Acquire D.O.R.C.
Carl Zeiss Meditec AG announced that they have entered into an agreement to acquire 100% of the shares in D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. from Eurazeo SE, based in Paris, France. The deal is worth €985 million (nearly $1.09 billion).
This acquisition is set to significantly enhance and complement ZEISS Medical Technology’s extensive ophthalmic portfolio, providing a comprehensive suite of digitally connected workflow solutions. The integration of D.O.R.C. into Carl Zeiss Meditec AG's offerings is poised to address a diverse array of eye conditions, ranging from retinal disorders and cataracts to glaucoma and refractive errors.
One of the key highlights of this acquisition is the inclusion of the EVA NEXUSTM platform, which stands as one of the market’s most advanced dual-function systems. The EVA NEXUSTM platform is the cornerstone of an impressive portfolio, featuring a dual-capable system alongside a complete range of accessories, instruments, and liquids. This comprehensive solution is designed to excel across various procedures, covering vitreoretinal (VR), cataract, and combined surgeries. Surgeons can now rely on a single platform to address a spectrum of procedure types, streamlining workflow and improving overall efficiency.
“With the acquisition of Dutch Ophthalmic Research Center, we’ll bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS’s position in the vitreo-retinal surgery segment and extend our leadership in the ophthalmic medical devices market,” says Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG.
“In the year when D.O.R.C. celebrates 40 years of surgeon-inspired innovation in ophthalmic surgery, we could not be more excited to join a market leader and visionary like ZEISS Medical Technology,” says Pierre Billardon, CEO of D.O.R.C. “We’ve built an amazing business with innovative, market-leading products and look forward to seizing this opportunity for growth and advancing the future of ophthalmic surgery. I am personally proud and immensely grateful to all of the team at D.O.R.C. for their commitment and expertise to help patients see again.”
The completion of the transaction is contingent upon obtaining necessary regulatory and antitrust approvals.
